Novartis, Gilead, GSK grab positive CHMPs; Menarini and Radius sign up to $350M partnership
→ The CHMP may have given a thumbs down on SOBI’s $568 million rare disease drug, but they handed out several positive opinions, including: …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
